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To evaluate feasibility, safety and efficacy of day-and-night hybrid closed-loop insulin 
delivery in adolescents with type 1 diabetes under free-living conditions without 
remote monitoring or supervision. 
Research Design and Methods 
In an open-label randomized free-living crossover study design, 12 adolescents on 
insulin pump therapy (age 15.4±2.6years; HbA1c 8.3±0.9%; duration of diabetes 
8.2±3.4years; mean±SD) underwent two seven-day periods of sensor-augmented 
insulin pump therapy or hybrid closed-loop insulin delivery without supervision or 
remote monitoring. During closed-loop, a model predictive algorithm automatically 
directed insulin delivery between meals and overnight; prandial boluses were 
administered by participants using a bolus calculator. 
Results  
The proportion of time when sensor glucose was in the target range (3.9 to 
10mmol/l) was increased during closed-loop compared to sensor-augmented pump 
therapy (72% vs. 53%, p<0.001; primary endpoint), mean glucose was lowered (8.7 
vs. 10.1mmol/l, p=0.028), and time spent above target was reduced (p=0.005) 
without changing the total daily insulin amount (p=0.55). Time spent in the 
hypoglycemic range was low and comparable between interventions.  
Conclusions  
Unsupervised day-and-night hybrid closed-loop at home is feasible and safe in 
young people with type 1 diabetes. Compared to sensor-augmented insulin pump 
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therapy, closed-loop may improve glucose control without increasing the risk of 




Childhood onset type 1 diabetes is associated with significant morbidity and 
reduced life expectancy resulting from dysglycemia-related acute and long-term 
complications (1; 2). Adolescence is a particularly vulnerable period for onset and 
priming of cardiovascular and renal complications (3; 4) while the majority of young 
people with type 1 diabetes do not meet treatment targets (5; 6). 
Diabetes management in adolescence is complicated by psychological and 
physiological changes accompanying puberty (7). Apart from hypoglycemia (8), 
reduced compliance is a major obstacle to achieving tight glucose control (9). 
Diabetic ketoacidosis is more common (10; 11), omission of or delayed insulin 
boluses with meals or snacks is widespread (9; 12), and discontinuation of insulin 
pump therapy is highest among adolescents (13). Sensor-augmented insulin pump 
therapy (14) and threshold-suspend features may alleviate burden of hypoglycemia 
and improve outcomes (15; 16), but acceptance and use of continuous glucose 
monitoring systems is notably reduced amongst teenagers (14; 17).  
The artificial pancreas or closed-loop systems differ from conventional pump 
therapy and threshold-suspend approaches through the use of a control algorithm 
that autonomously and continually increases and decreases subcutaneous insulin 
delivery based on real-time sensor glucose levels (18). Results from studies under 
controlled laboratory settings (19-23) and investigations of closed-loop in transitional 
outpatient settings, incorporating remote monitoring and supervision by research 
staff in hotels (24) or at diabetes camps (25; 26), have demonstrated improved 
glucose control and reduction of hypoglycemia (25-28). First at-home studies of 
three weeks to three months application of overnight close-loop have been 
performed in adolescents and adults (29-32). However, home studies of 
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unsupervised day-and-night closed-loop application have been restricted to adults 
only (32; 33). There has been no previous evaluation of unsupervised day-and-night 
closed-loop in free-living settings in adolescents aged 10 to 18 years. 
Here, we present the results of a seven-day-long day-and-night closed-loop 
home trial in adolescents with type 1 diabetes under free-living conditions. We 
hypothesized that day-and-night use of hybrid closed-loop insulin delivery without 
remote monitoring is feasible, safe and could improve glycemic control compared to 
sensor-augmented pump therapy in this population.  
 
RESEARCH DESIGN AND METHODS 
Study management and regulatory approvals 
Prior to study initialization, approval was sought and received from the local 
independent research ethics committee and the UK regulatory authority (Medicines 
& Health products Regulatory Agency). An independent Data Safety and Monitoring 
Board oversaw the study and was informed of all unanticipated adverse events that 
occurred during the study. 
Participants 
Study participants were recruited between August 2014 and October 2014 
through the pediatric diabetes clinic at Addenbrooke’s Hospital, Cambridge, UK. Key 
inclusion criteria were age 10-18 years, diagnosis of type 1 diabetes, treatment with 
insulin pump therapy for at least three months, willingness to perform at least four 
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fingerstick glucose measurements per day, and HbA1c ≤11% (97mmol/mol). 
Exclusion criteria included established nephropathy, neuropathy, or proliferative 
retinopathy, total daily insulin dose ≥2.0 U/kg or <10 U/day, concurrent illness or 
medications likely to interfere with interpretation of study results, significant 
hypoglycemia unawareness as judged by the clinical investigators, recurrent 
incidents of severe hypoglycemia as defined by International Society for Pediatric 
and Adolescent Diabetes guidelines during the previous six months, more than one 
episode of diabetic ketoacidosis within 12 months prior to enrolment, pregnancy and 
breast-feeding. Participants aged ≥16 years and parents or guardians of participants 
aged <16 years signed informed consent; written assent was obtained from minors.  
Study design  
The study adopted an open-label prospective single center randomized 
crossover design contrasting automated closed-loop insulin delivery and sensor-
augmented pump therapy over seven days (Supplemental Figure S1). The study 
was performed under free-living home conditions without remote monitoring or 
supervision by research staff, and participants performed their usual daily living 
activities. The participants were free to consume any meals of their choice and no 
restrictions were imposed on travelling or moderate exercise. All participants had 
access to a 24-hour telephone helpline to contact the study team in the event of 
study-related issues. 
Study procedures 
Blood samples for baseline HbA1c and non-hypoglycemia C-peptide levels 
were taken at enrolment. At the start of the run-in phase, participants were trained on 
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the use of the study insulin pump (DANA Diabecare R; Sooil, Seoul, South Korea) 
and study real-time continuous glucose monitoring device (FreeStyle Navigator II; 
Abbott Diabetes Care, Alameda, CA). The study insulin pump was programmed with 
the participant’s usual basal settings, usual insulin-to-carbohydrate ratios and 
correction factors and delivered rapid-acting insulin analog (insulin aAspart, Novo 
Nordisk, Bagsvaerd, Denmark; or insulin lisproHumalog, Eli Lilly, Indianapolis, US). 
Participants were advised to use the bolus calculator for all meals during the entire 
study. Ability and competency to use study devices was formally assessed and 
additional training was provided as required. Over a one to two week run-in phase, 
participants were required to use the study pump and collect at least five days worth 
of sensor glucose to pass the compliance assessment. Data obtained during run-in 
phase were utilized for therapy optimization as per usual clinical practice. 
After the run-in period, participants underwent two seven day periods, in 
random order, during which glucose was controlled either by sensor-augmented 
insulin pump therapy or hybrid closed-loop insulin delivery. The two treatment 
interventions were separated by one to four week wash-out period during which the 
participants could continue using the study insulin pump applying their standard 
pump settings. Continuous glucose monitoring was discontinued during wash-out. 
The participants had the same number of planned contacts with the study 
team during the two study periods and used the study pump and the study real-time 
continuous glucose monitoring device during both study periods. 
Randomization assignment was unblinded, but allocation between treatment 
sequences was concealed to the study staff until after randomization, which occurred 
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the day prior to the first intervention. Random permuted blocks were used for 
treatment sequence allocation. 
On the first day of the closed-loop period, a two to three hour training session 
was provided by the investigators at the clinical research facility, including initiation 
and discontinuation of the closed-loop system, switching between closed-loop and 
usual pump therapy, meal bolus procedure, and the use of study devices during 
exercise. Prandial boluses were advised to be delivered before the meals using the 
pump’s standard bolus calculator. Competency on the use of closed-loop system 
was assessed prior to discharge. After the training session, participants continued 
the study intervention for the next seven days under free-living conditions in their 
home and school environment. Automated closed-loop insulin delivery was 
continued during exercise of mild to moderate intensity, and exercise was 
announced to the algorithm. Participants were advised to discontinue closed-loop 
and follow their usual insulin pump therapy for certain activities such as periods of 
strenuous exercise, diving or contact sports. 
Participants were advised to calibrate the continuous glucose monitoring 
device according to the manufacturer’s instructions, and use the built-in glucometer 
for all fingerstick measurements; they were free to decide on alarm thresholds for the 
continuous glucose monitoring device. Participants followed their standard clinic 
guidelines for hypoglycemia and hyperglycemia treatment. 
Closed-loop system 
The FlorenceD2A closed-loop system (University of Cambridge, Cambridge, 
UK)(34) comprised a model predictive control algorithm (version 0.3.30, University of 
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Cambridge) residing on a smartphone (Nexus 4, LG, South Korea), which 
communicated wirelessly with continuous glucose monitoring receiver through a 
purpose made translator unit (Triteq, Hungerford, UK) (Supplemental Figure S2). 
Every 12 min, the control algorithm calculated a new insulin infusion rate which was 
automatically set on the study insulin pump. The calculations utilized a compartment 
model of glucose kinetics (35) describing the effect of rapid-acting insulin analogues 
and the carbohydrate content of meals on glucose levels. In this trial, a hybrid 
closed-loop approach was applied, in which participants additionally administered 
prandial insulin for all meals using the standard bolus calculator. The control 
algorithm was initialized using preprogrammed basal insulin doses downloaded from 
the study pump. Additionally, information about participant's weight and total daily 
insulin dose were entered at setup. During closed-loop operation, the algorithm 
adapted itself to the particular participant. The treat-to-target control algorithm aimed 
to achieve glucose levels between 5.8mmol/l and 7.3mmol/l and adjusted the actual 
level depending on fasting versus postprandial status and the accuracy of model-
based glucose predictions. Though devices were advised to be kept in vicinity to 
each other, a wireless transmission range of several meters allowed for flexibility in 
terms of device wear, appropriate cases, clips and pouches were provided. 
The continuous glucose monitoring receiver provided hypoglycemia and 
hyperglycemia alarms, the insulin pump provided standard alarms, and the 
smartphone alerted the user about aspects related to closed-loop operation such as 
when closed-loop started or stopped.  
Safety precautions during closed-loop 
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Participants performed a calibration check before breakfast and the evening 
meal. If the sensor glucose was above the fingerstick glucose by >3.0mmol/l, the 
continuous glucose monitoring device was manually recalibrated. There was no 
recalibration for sensor under reading. These instructions resulted from an in silico 
evaluation of hypoglycemia and hyperglycemia risk (36) using the validated 
Cambridge simulator (37). 
If sensor glucose became unavailable or in case of other failures, 
preprogrammed insulin delivery automatically restarted within 30-60 min. This limited 
the risk of insulin under- and over delivery (36). Safety rules limited maximum insulin 
infusion and suspended insulin delivery if glucose was ≤4.3 mmol/l or when sensor 
glucose was rapidly decreasing.  
Assays 
HbA1c was measured using ion exchange high performance liquid 
chromatography (G8 HPLC Analyzer, Tosoh Bioscience Inc., CA, US; interassay 
CVs 1.3% at 31.2mmol/mol, 0.8% at 80.5mmol/mol). C-peptide measurements were 
performed using chemiluminescence immunoassay (IV2-004; Invitron Ltd, 
Monmouth UK; inter-assay variation 7.8%, 4.3% and 6.7% at 268pmol/l, 990pmol/l 
and 1,862pmol/l, respectively). Analytical sensitivity for the C-peptide assay was 
5pmol/l.  
Study outcomes 
The primary outcome was the proportion of time when glucose was in the 
target range (3.9-10.0mmol/l) during the seven day study periods. Secondary 
11 
 
outcomes included mean sensor glucose levels, glucose variability, and time spent 
below and above glucose target. Outcomes were calculated during day-and-night, 
daytime and overnight periods; daytime was classified between 08:00 and midnight, 
and nighttime between midnight and 08:00. Glucose variability was assessed by the 
standard deviation and the coefficient of variation of sensor glucose. Hypoglycemia 
burden was assessed by calculating the glucose sensor area under the curve less 
than 3.5mmol/l.  
 
Statistical analysis 
The statistical analysis plan was agreed upon by investigators in advance. All 
analyses were undertaken on an intention-to-treat basis. Efficacy and safety data 
from all randomized participants with or without protocol violation were included in 
the analyses. The respective values obtained during the seven day randomized 
interventions contrasting the closed-loop system against the sensor-augmented 
pump therapy were compared using a least-square regression model. Sensor 
glucose outcomes were adjusted for baseline glucose level and period effect; insulin 
outcomes for period effect. Rank normal transformation analyses were used for 
highly skewed endpoints. Outcomes were presented as mean ± SD for normally 
distributed values or as median (interquartile range) for non-normally distributed 
values. Secondary outcomes for daytime and nighttime periods were excluded from 
calculating p-values to limit multiple comparisons. Outcomes were calculated using 
GStat software (University of Cambridge, version 2.2). Analysis was done using SAS 
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(SAS Institute, USA, version 9.4). A 5% significance level was used to declare 




Fourteen subjects were screened. Supplemental Figure S3 shows the flow of 
participants through the study. One participant did not meet the inclusion/exclusion 
criteria, and another voluntarily withdrew consent and did not complete the run-in 
phase. Twelve eligible participants were randomized, completed the study, and 
provided data for analyses (8 males; age 15.4±2.6 years; diabetes duration 8.2±3.4 
years; HbA1c 8.3±0.9% [68±10mmol/mol]; insulin pump therapy duration 
5.6±2.9years; total daily insulin dose 0.84±0.22 U/kg/day]) (Supplemental Table S1).  
Day-and-night glucose control and insulin delivery  
The primary endpoint, the proportion of time sensor glucose was in the target 
glucose range 3.9 to 10.0mmol/l, significantly increased during closed-loop (p<0.001, 
Table 1). Twenty-four hour sensor glucose and insulin delivery profiles are shown in 
Figure 1. Closed-loop significantly reduced the mean glucose (p=0.028 ) and time 
spent above target glucose level (p=0.005) without increasing time spent in 
hypoglycemia (Table 1 and Figure 2). Proportion of time when sensor glucose was in 
hypoglycemic range (below 3.9mmol/l and 2.8mmol/l) and the area under the curve 




There was no difference in glucose variability between study periods as 
measured by the standard deviation and coefficient of variation of sensor glucose. 
Increased time when glucose was in target range and reduced mean glucose was 
achieved by closed-loop through increased variability of basal insulin delivery but 
without increasing total daily insulin (p=0.55). Higher total basal insulin delivery 
during closed-loop (p=0.001) was offset by a trend towards lower bolus delivery 
(p=0.06) presumably due to lower glucose levels resulting in reduced correction 
boluses (Table 1). 
Daytime and overnight glucose control and insulin delivery  
Secondary outcomes calculated for daytime and overnight periods are shown 
in Supplemental Table S2. Daytime and overnight outcomes were similar to 
outcomes over day-and-night. Proportion of time when sensor glucose was in 
daytime target range (3.9 to 10.0mmol/l) and overnight target range (3.9 to 
8.0mmol/l) tended to be higher during closed-loop compared to control [daytime: 
66% (55% to 68%) vs. 49% (46% to 51%); overnight: 63% (49% to 78%) vs. 40% 
(30% to 48%)]. Daytime mean glucose (9.4±1.2mmol/l vs. 10.3±1.4mmol/l)] and 
overnight mean glucose (7.8±1.8mmol/l vs. 9.7±1.8mmol/l)] tended to be lower 
during closed-loop without a difference in total daytime and overnight insulin amount.  
Adverse events 
No serious adverse events or severe hypoglycemic episodes were observed 
during either study period. Two participants measured mild to moderate elevated 
blood ketones (>2.00mmol/l) associated with hyperglycemia, one participant during 
closed-loop and one participant in the control period. These events were attributed to 




Closed-loop was operational over 91% (75% to 96%)] of time. Availability of 
sensor glucose was 98% (93% to 100%)] during closed-loop and 97% (92% to 
100%)] during control period. On average, closed-loop was interrupted 1.1 times (0.6 
to 1.5)] per subject per day. Apart from two occasions requiring closed-loop system 
reset by research staff, the participants were able to resolve issues on their own, 







To our knowledge, this is the first trial investigating day-and-night application 
of closed-loop insulin delivery under free-living conditions in adolescents with type 1 
diabetes. Results of the present study demonstrate the feasibility of unsupervised 
free-living home use of 24/7 hybrid closed-loop in this challenging population. 
Closed-loop increased the time when glucose was in the target range while reducing 
the mean glucose. These improvements were achieved without increasing the risk of 
hypoglycemia and without increasing the total daily insulin dose. 
The occurrence of hypoglycemia exposure in the present study was low. 
Compared with previously published day-and-night adult outpatient studies using 
single-hormone (32; 33) or dual-hormone approaches with glucagon co-
administration (27), participants in the present study spent less time at glucose levels 
below 3.9mmol/l during control period. During the closed-loop study arm our results 
matched the findings observed in adults (Table 2). In our adolescent cohort, the 24/7 
hybrid closed-loop system managed to keep time in hypoglycemia on a low level, 
while significant reductions in hypoglycemia risk using closed-loop in outpatient 
settings were seen in more hypoglycemia prone populations (27, 32, 33). 
The advent of novel technologies such as threshold-suspend insulin pump 
therapy (15) and more recently predictive low glucose suspend (16) may reduce 
hypoglycemia risk. However, these approaches are not designed to increase insulin 
delivery and do not address the issue of hyperglycemia, which poses major 
challenges in diabetes management of adolescents. The important advantage of a 
closed-loop system is highly responsive graduated modulation of insulin delivery 
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both below and above the pre-set pump regimen, allowing for improvements in time 
spent with target glucose values and reduction of mean glucose without increased 
hypoglycemia. 
Closed-loop use and sensor wear were high in our cohort. This may be 
attributed to the relatively short intervention period and motivational bias of study 
participants. These findings are in line with previous observations regarding 
overnight closed-loop home application over longer intervention periods in 
adolescents (31). In terms of psychosocial impact and acceptance, overnight closed-
loop technology was well accepted in this age group, with overall benefits 
outweighing practical challenges such as technical difficulties, intrusiveness of 
alarms, and size of the devices (38). Given high closed-loop utilisation in 
adolescents, the positive perception of this technology and its benefits in terms of 
glycemic control demonstrated by the present study, closed-loop represents a 
promising tool to address glycemic deterioration (7; 39) and reduced adherence 
commonly seen in adolescence (7; 39) (40). 
The strengths of our study include the integration of closed-loop into normal 
life including use at school, and during weekends and holidays. The study was 
performed without remote monitoring or close supervision. No restrictions were 
imposed on dietary intake, moderate physical activity or travel. The comparator was 
‘state-of-the-art’ sensor-augmented insulin pump therapy. A crossover design had 
the benefit of each participant acting as his/her own control. Weaknesses include the 
small sample size, theand relatively short study duration, and limited use of the 
closed-loop system during strenuous exercise. The current closed-loop prototype 
system requires participants to wear and carry multiple devices. Further integration 
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of devices may reduce this burden and enhance usability of closed-loop systems, 
particularly during physical activity. A more adaptive control algorithm might further 
enhance daytime benefits. 
In conclusion, we have demonstrated that day-and-night hybrid closed-loop 
can be used safely in adolescents at home without supervision. Its benefits include 
increased time when glucose is in the target range and reduced mean glucose. 




Results of this trial were presented as an oral communication at the 75th ADA 
scientific sessions in Boston, MA, June 5-9, 2015. 
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Table 1.  Comparison of glucose control and insulin delivery during closed-







Time spent at glucose level (%)    
 3.9 to 10.0mmol/l* 72 (59 to 77) 53 (46 to 59) <0.001 
 >10.0mmol/l 26 (21 to 35) 43 (38 to 52) 0.005 
 <3.9mmol/l 2.9 (1.8 to 4.8) 1.7 (0.9 to 5.1) 0.87 
 <2.8mmol/l 0.2 (0.0 to 0.6) 0.1 (0.0 to 0.6) 0.67 
AUCday <3.5mmol/l (mmol/l x min)
 †
 6.4 (2.8 to 23.7) 4.3 (1.8 to 13.6) 0.77 
Mean glucose (mmol/l) 8.7±1.1 10.1±1.3 0.028 
Within day SD of glucose (mmol/l) 3.5 (3.3 to 4.2) 4.0 (3.6 to 4.6) 0.21 
CV of glucose within day (%) 41 (40 to 45) 39 (38 to 44) 0.36 
CV of glucose between days (%) 17 (11 to 22) 19 (17 to 25) 0.80 
Total daily dose (U/day) 57.3 (45.6 to 65.2) 56.6 (44.7 to 61.3) 0.55 
Total bolus (U/day) 31.9 (21.2 to 41.0) 38.3 (26.4 to 41.4) 0.06 
Total basal (U/day) 24.3 (22.8 to 28.8) 20.3 (19.1 to 22.1) 0.001 
CV of basal insulin (%) 94 (91 to 103) 16 (13 to 26) <0.001 
Data are presented as mean±SD or median (interquartile range) 
* Primary endpoint 
† 
AUCday, glucose area under curve below 3.5mmol/l per day 
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Time spent at glucose level  





       
Adults* mixed
†
 20 5 days 4.1±3.5 7.3±4.7 (27) 
Adults
‡
 home 17 1 week 3.1±2.6 4.3±3.6 (33) 
Adults
‡
 home 33 12 weeks 3.1±1.9 4.3±3.9 (32) 
Adolescents
‡
 home 12 1 week 3.7±2.7 3.3±3.7 present study 
 
Data are presented as mean±SD 
* Dual-hormone closed-loop vs. usual care (45% of participants used real-time continuous glucose monitoring during usual care) 
†
 Control: home; closed-loop: restricted geographical area during day & hotel overnight 
‡ 
Single-hormone closed-loop vs. sensor-augmented pump therapy 
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Figure 1.  Median (interquartile range) of sensor glucose (top panel) and 
insulin delivery (bottom panel) during closed-loop (solid red line and red 
shaded area) and control period (dashed black line and gray shaded area) from 
midnight to midnight. The glucose range 3.9 to 10.0 mmol/l is denoted by 




Figure 2. Individual values of  mean sensor glucose during day-and-night 
closed-loop study. The size of bubble indicates the proportion of time spent 
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